Efek Tetes Mata Kombinasi Sodium Hialuronat dan Hydroxypropyl-Guar terhadap Stabilitas Lapisan Air Mata pada Mata Kering Terkait Sindrom Sjögren
DOI:
https://doi.org/10.55175/cdk.v46i1.521Kata Kunci:
Hydroxypropyl (HP)-guar, NIKBUT, mata kering, sindrom Sjögren, sodium hialuronatAbstrak
Penelitian ini bertujuan untuk menilai stabilitas lapisan air mata pada mata kering terkait sindrom Sjögren (SS) yang diberi terapi tetes mata kombinasi sodium hialuronat 0,1% (SH) dan hydroxypropyl (HP)-guar, atau monoterapi tetes mata sodium hialuronat (SH). Sebanyak 17 pasien SS dibagi dalam 2 kelompok. Kelompok pertama mendapat kombinasi SH dan HP-guar, kelompok kedua mendapat terapi SH. NIKBUT, Schirmer, skor pewarnaan okular, dan sitologi impresi, serta keluhan subjektif dinilai sebelum dan sesudah pemberian obat. Setelah terapi selama 28 hari, terdapat peningkatan median NIKBUT, Schirmer, skor pewarnaan okular, densitas sel Goblet, dan perbaikan keluhan subjektif pada mata kering terkait SS.
The objectives of the study is to assess the stability of dry eye LAM associated with Sjögren syndrome (SS) during combination therapy of sodium hyaluronate 0.1% (SH) and hydroxypropyl (HP) -guar, or monotherapy sodium hyaluronic (SH). A total of 17 SS patients in this study were divided into 2 groups. The first group received a combination of SH and HP-guar while the second group received SH therapy. NIKBUT, Schirmer, ocular staining score, and impression cytology, as well as subjective complaints was assessed before and after drug administration. After 28 days of therapy, there was a median increase in NIKBUT, Schirmer, ocular staining scores, Goblet cell density, and subjective complaints on SS-related dry eyes.
Unduhan
Referensi
Beckman KA, Luchs J, Milner MS. Making the diagnosis of Sjogren's syndrome in patients with dry eye. Clini Ophthalmol. 2016;10:43-53.
Samarkos M, Moutsopoulos HM. Recent advances in the management of ocular complications of Sjogren's syndrome. Curr Allerg Asthma Rep. 2005;5(4):327-32.
Yokoi N, Sonomura Y, Kato H, Komuro A, Kinoshita S. Three percent diquafosol ophthalmic solution as an additional therapy to existing artificial tears with steroids for dry-eye patients with Sjogren's syndrome. Eye. 2015;29(9):1204-12.
Akpek EK, Klimava A, Thorne JE, Martin D, Lekhanont K, Ostrovsky A. Evaluation of patients with dry eye for presence of underlying Sjogren syndrome. Cornea. 2009;28(5):493-7.
Fox RI. Sjogren's syndrome. Lancet. 2005;366(9482):321-31.
Matossian C, Micucci J. Characterization of the serological biomarkers associated with Sjogren's syndrome in patients with recalcitrant dry eye disease. Clini Ophthalmol. 2016;10:1329-34.
Patel R, Shahane A. The epidemiology of Sjogren's syndrome. Clinical Epidemiol. 2014;6:247-55.
Bjerrum KB. Keratoconjunctivitis sicca and primary Sjogren's syndrome in a Danish population aged 30-60 years. Acta ophthalmologica Scandinavica. 1997;75(3):281-6.
Mavragani CP, Moutsopoulos HM. Sjogren syndrome. Canad Med Assoc J. 2014;186(15):579-86.
Westhoff G, Zink A. Epidemiology of primary Sjorgren's syndrome. Zeitschrift fur Rheumatologie. 2010;69(1):41-9.
Tishler M, Yaron I, Geyer O, Shirazi I, Naftaliev E, Yaron M. Elevated tear interleukin-6 levels in patients with Sjogren syndrome. Ophthalmol. 1998;105(12):2327-9.
Akpek EK, Lindsley KB, Adyanthaya RS, Swamy R, Baer AN, McDonnell PJ. Treatment of Sjogren's syndrome-associated dry eye an evidence-based review. Ophthalmol. 2011;118(7):1242-52.
Foulks GN, Forstot SL, Donshik PC, Forstot JZ, Goldstein MH, Lemp MA, et al. Clinical guidelines for management of dry eye associated with Sjogren disease. The Ocular Surface. 2015;13(2):118-32.
Hyon JY, Lee YJ, Yun PY. Management of ocular surface inflammation in Sjogren syndrome. Cornea. 2007;26(9 Suppl1):13-5.
Lin T, Gong L. Topical fluorometholone treatment for ocular dryness in patients with Sjogren syndrome: A randomized clinical trial in China. Medicine. 2015;94(7):551.
Ousler GW, Michaelson C, Christensen MT. An evaluation of tear film breakup time extension and ocular protection index scores among three marketed lubricant eye drops. Cornea. 2007;26(8):949-52.
Wu D, Chen WQ, Li R, Wang Y. Efficacy and safety of topical diquafosol ophthalmic solution for treatment of dry eye: A systematic review of randomized clinical trials. Cornea. 2015;34(6):644-50.
Marsh P, Pflugfelder SC. Topical nonpreserved methylprednisolone therapy for keratoconjunctivitis sicca in Sjogren syndrome. Ophthalmol. 1999;106(4):811-6.
Hartstein I, Khwarg S, Przydryga J. An open-label evaluation of HP-Guar gellable lubricant eye drops for the improvement of dry eye signs and symptoms in a moderate dry eye adult population. Curr Med Res Opini. 2005;21(2):255-60.
Rolando M, Autori S, Badino F, Barabino S. Protecting the ocular surface and improving the quality of life of dry eye patients: a study of the efficacy of an HP-guar containing ocular lubricant in a population of dry eye patients. J Ocular Pharmacol Therapeut. 2009;25(3):271-8.
Aragona P, Papa V, Micali A, Santocono M, Milazzo G. Long term treatment with sodium hyaluronate-containing artificial tears reduces ocular surface damage in patients with dry eye. Br J Ophthalmol. 2002;86(2):181-4.
Kamiya K, Nakanishi M, Ishii R, Kobashi H, Igarashi A, Sato N, et al. Clinicalevaluation of the additive effect of diquafosol tetrasodium on sodium hyaluronate monotherapy in patients with dry eye syndrome: A prospective, randomized, multicenter study. Eye. 2012;26(10):1363-8.
Tong L, Petznick A, Lee S, Tan J. Choice of artificial tear formulation for patients with dry eye: Where do we start? Cornea. 2012;31(Suppl1):32-6.
Benelli U. Systane lubricant eye drops in the management of ocular dryness. Clin Ophthalmol. 2011;5:783-90.
Erin Peters KC. Duane's foundations of clinical ophthalmology. In: Tasman WJ, Edward A, editors. Physiology of the eye and visual system: The tear film. 2009.
Stern ME, Gao J, Siemasko KF, Beuerman RW, Pflugfelder SC. The role of the lacrimal functional unit in the pathophysiology of dry eye. Experimental Eye Res. 2004;78(3):409-16.
Gipson IK, Argueso P. Role of mucins in the function of the corneal and conjunctival epithelia. Internat Rev Cytology. 2003;231:1-49.
Louis B. Cantor CJR, George A. Cioffi. External eye disease and cornea. San Francisco: Am Acad Ophthalmol;2014-2015.
Louis B. Cantor CJR, George A. Cioffi. Fundamentals and principals of ophthalmology. San Francisco: Am Acad Ophthalmol;2014-2015.
Argueso P, Gipson IK. Epithelial mucins of the ocular surface: structure, biosynthesis and function. Experimental Eye Res.2001;73(3):281-9.
Springs CL. Novel hydroxypropyl-guar gellable lubricant eye drops for treatment of dry eye. Advances in therapy.2010;27(10):681-90.
Pflugfelder SC, Solomon A, Stern ME. The diagnosis and management of dry eye: a twenty-five-year review. Cornea.2000;19(5):644-9.
He J, Bazan NG, Bazan HE. Mapping the entire human corneal nerve architecture. . Experimental Eye Res.2010;91(4):513-23.
Gumus K, Cavanagh DH. The role of inflammation and antiinflammation therapies in keratoconjunctivitis sicca. Clinical Ophthalmol.2009;3:57-67.
Christine Delporte JPaMSS. Primary Sjö gren’s Syndrome: Current Pathophysiological, Diagnostic and Therapeutic Advances. In: Huang F-P, editor. Autoimmune Disorders - Current Concepts and Advances from Bedside to Mechanistic Insights. Belgium: InTech; 2011. p.41-66.
Tincani A, Andreoli L, Cavazzana I, Doria A, Favero M, Fenini MG, et al. Novel aspects of Sjogren's syndrome in 2012. BMC Med.2013;11:93.
Fazaa A, Bourcier T, Chatelus E, Sordet C, Theulin A, Sibilia J, et al. Classification criteria and treatment modalities in primary Sjogren's syndrome. Expert Rev Clin Immunol.2014;10(4):543-51.
The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop (2007). The Ocular Surface. 2007;5(2):75-92.
Connor CG, Flockencier LL, Hall CW. The influence of gender on the ocular surface. J Am Optom Assoc.1999;70(3):182-6.
Gayton JL. Etiology, prevalence, and treatment of dry eye disease. Clin Ophthalmol.2009;3:405-12.
Lin H, Yiu SC. Dry eye disease: A review of diagnostic approaches and treatments. Saudi J Ophthalmol. 2014;28(3):173-81.
Barabino S, Labetoulle M, Rolando M, Messmer EM. Understanding Symptoms and Quality of Life in Patients With Dry Eye Syndrome. The Ocular Surface.2016;14(3):365-76.
Duane's Ophthalmology. In: Tasman WJ, Edward A, eds. 2: Lippincott Williams & Wilkins;2009.
McGinnigle S, Naroo SA, Eperjesi F. Evaluation of dry eye. Survey of Ophthalmol. 2012;57(4):293-316.
Kastelan S, Tomic M, Salopek-Rabatic J, Novak B. Diagnostic procedures and management of dry eye. BioMed Res Internati.2013;2013:309723.
Messmer EM. The pathophysiology, diagnosis, and treatment of dry eye disease. Deutsch Arzteblatt Internat. 2015;112(5):71-81; quiz2.
Bron AJ, Evans VE, Smith JA. Grading of corneal and conjunctival staining in the context of other dry eye tests. Cornea.2003;22(7):640-50.
Whitcher JP, Shiboski CH, Shiboski SC, Heidenreich AM, Kitagawa K, Zhang S, et al. A simplified quantitative method for assessing keratoconjunctivitis sicca from the Sjogren's Syndrome International Registry. Am J Ophthalmol.2010;149(3):405-15.
Singh R, Joseph A, Umapathy T, Tint NL, Dua HS. Impression cytology of the ocular surface. Br J Ophthalmol.2005;89(12):1655-9.
Gillan W. Conjunctival impression cytology: a review. Johannesburg 2008. 136-41p.
Calonge M, Diebold Y, Saez V, Enriquez de Salamanca A, Garcia-Vazquez C, Corrales RM, et al. Impression cytology of the ocular surface: a review. Experimental Eye Res. 2004;78(3):457-72.
Condon PI, McEwen CG, Wright M, Mackintosh G, Prescott RJ, McDonald C. Double blind, randomised, placebo controlled, crossover, multicentre study to determine the efficacy of a 0.1% (w/v) sodium hyaluronate solution (Fermavisc) in the treatment of dry eye syndrome. Br J Ophthalmol.1999;83(10):1121-4.
Christensen MT. Corneal staining reductions observed after treatment with Systane Lubricant Eye Drops. Advances in therapy.2008;25(11):1191-9.
Aguilar AJ, Marquez MI, Albera PA, Tredicce JL, Berra A. Effects of Systane((R)) Balance on noninvasive tear film break-up time in patients with lipid-deficient dry eye. Clin Ophthalmol. 2014;8:2365-72.
Yang JM, Choi W, Kim N, Yoon KC. Comparison of Topical Cyclosporine and Diquafosol Treatment in Dry Eye. Optometry and Vision.2015;92(9):e296-302.
Koh S, Ikeda C, Takai Y, Watanabe H, Maeda N, Nishida K. Long-term results of treatment with diquafosol ophthalmic solution for aqueous-deficient dry eye. Jap J Ophthalmol.2013;57(5):440-6.
Schiffman RM, Christianson MD, Jacobsen G, Hirsch JD, Reis BL. Reliability and validity of the Ocular Surface Disease Index. Arch Ophthalmol.2000;118(5):615-21.
Shimazaki J, Goto E, Ono M, Shimmura S, Tsubota K. Meibomian gland dysfunction in patients with Sjogren syndrome. Ophthalmol.1998;105(8):1485-8.
Carubbi F, Cipriani P, Marrelli A, Benedetto P, Ruscitti P, Berardicurti O, et al. Efficacy and safety of rituximab treatment in early primary Sjogren's syndrome: a prospective, multi-center, follow-up study. Arthritis Res Ther.2013;15(5):R172.
Meijer JM, Meiners PM, Vissink A, Spijkervet FK, Abdulahad W, Kamminga N, et al. Effectiveness of rituximab treatment in primary Sjogren's syndrome: a randomized, double-blind, placebo-controlled trial. Arthritis Rheumatism.2010;62(4):960-8.
Aragona P, Di Stefano G, Ferreri F, Spinella R, Stilo A. Sodium hyaluronate eye drops of different osmolarity for the treatment of dry eye in Sjogren's syndrome patients. Br J Ophthalmol.2002;86(8):879-84.
Alamanos Y, Tsifetaki N, Voulgari PV, Venetsanopoulou AI, Siozos C, Drosos AA. Epidemiology of primary Sjogren's syndrome in north-west Greece, 1982-2003. Rheumatol. 2006;45(2):187-91.
Plesivcnik Novljan M, Rozman B, Hocevar A, Grmek M, Kveder T, Tomsic M. Incidence of primary Sjogren's syndrome in Slovenia. Ann Rheumatic Dis. 2004;63(7):874-6.
Richards SM, Jensen RV, Liu M, Sullivan BD, Lombardi MJ, Rowley P, et al. Influence of sex on gene expression in the mouse lacrimal gland. Experimental Eye Res. 2006;82(1):13- 23.
Konttinen YT, Fuellen G, Bing Y, Porola P, Stegaev V, Trokovic N, et al. Sex steroids in Sjogren's syndrome. J Autoimmunity.2012;39(1-2):49-56.
Calonge M, Enriquez-de-Salamanca A, Diebold Y, Gonzalez-Garcia MJ, Reinoso R, Herreras JM, et al. Dry eye disease as an inflammatory disorder. Ocular Immunol Inflammation.2010;18(4):244-53.
Porola P, Laine M, Virkki L, Poduval P, Konttinen YT. The influence of sex steroids on Sjogren's syndrome. Ann NY Acad Sci.2007;1108:426-32.
Gensheimer WG, Kleinman DM, Gonzalez MO, Sobti D, Cooper ER, Smits G, et al. Novel formulation of glycerin 1% artificial tears extends tear film break-up time compared with Systane lubricant eye drops. J Ocular Pharmacol Therapeut. 2012;28(5):473-8.
Koh S, Ikeda C, Watanabe S, Oie Y, Soma T, Watanabe H, et al. Effect of non-invasive tear stability assessment on tear meniscus height. Acta Ophthalmol.2015;93(2):e135-9.
Tian L, Qu JH, Zhang XY, Sun XG. Repeatability and Reproducibility of Noninvasive Keratograph 5M Measurements in Patients with Dry Eye Disease. J Ophthalmol. 2016;2016:8013621.
Jacobi C, Kruse FE, Cursiefen C. Prospective, randomized, controlled comparison of SYSTANE UD eye drops versus VISINE INTENSIV 1% EDO eye drops for the treatment of moderate dry eye. J Ocular Pharmacol Therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.2012;28(6):598-603.
Ubels JL, Clousing DP, Van Haitsma TA, Hong BS, Stauffer P, Asgharian B, et al. Pre- clinical investigation of the efficacy of an artificial tear solution containing hydroxypropyl-guar as a gelling agent. Curr Eye Res.2004;28(6):437-44.
Uchiyama E, Di Pascuale MA, Butovich IA, McCulley JP. Impact on ocular surface evaporation of an artificial tear solution containing hydroxypropyl guar. Eye & Contact Lens. 2008;34(6):331-4.
Hamrah P, Alipour F, Jiang S, Sohn JH, Foulks GN. Optimizing evaluation of Lissamine Green parameters for ocular surface staining. Eye.2011;25(11):1429-34.
Schindelar M, Ousler, G.W. III, Abelson, M.B. Effect of tearfilm stability on ocular surface damage in a population of dryeyepatients. Invest Ophthalmol Vis Sci. 2005;46(E-Abstract 4457).
Gifford P, Evans BJ, Morris J. A clinical evaluation of Systane. Contact Lens & Anterior Eye.2006;29(1):31-40.
De Paiva CS, Corrales RM, Villarreal AL, Farley WJ, Li DQ, Stern ME, et al. Corticosteroid and doxycycline suppress MMP-9 and inflammatory cytokine expression, MAPK activation in the corneal epithelium in experimental dry eye. Experiment Eye Res. 2006;83(3):526-35.
Yeh S, Song XJ, Farley W, Li DQ, Stern ME, Pflugfelder SC. Apoptosis of ocular surface cells in experimentally induced dry eye. Investig Ophthalmol Visual Sci. 2003;44(1):124-9.
Brignole F, Pisella PJ, Goldschild M, De Saint Jean M, Goguel A, Baudouin C. Flow cytometric analysis of inflammatory markers in conjunctival epithelial cells of patients with dry eyes. Investig Ophthalmol Visual Sci.2000;41(6):1356-63.
Kunert KS, Tisdale AS, Gipson IK. Goblet cell numbers and epithelial proliferation in the conjunctiva of patients with dry eye syndrome treated with cyclosporine. Arch Ophthalmol.2002;120(3):330-7.
Pflugfelder SC, Huang AJ, Feuer W, Chuchovski PT, Pereira IC, Tseng SC. Conjunctival cytologic features of primary Sjogren's syndrome. Ophthalmol.1990;97(8):985-91.
Llamas-Moreno JF, Baiza-Duran LM, Saucedo-Rodriguez LR, Alaniz-De la OJ. Efficacy and safety of chondroitin sulfate/xanthan gum versus polyethylene glycol/propylene glycol/hydroxypropyl guar in patients with dry eye. Clinical Ophthalmol. 2013;7:995-9.
Unduhan
Diterbitkan
Cara Mengutip
Terbitan
Bagian
Lisensi
Hak Cipta (c) 2019 https://creativecommons.org/licenses/by-nc/4.0/
Artikel ini berlisensi Creative Commons Attribution-NonCommercial 4.0 International License.
